Published June 3, 2026 | Version v1
Preprint Open

Pulmonary Sarcoidosis as a Disseminated Bacteroidosis A Deep Mapping of potential relevance of Disseminated Enterotoxigenic Bacteroides fragilis Pathogenicity in Sarcoidosis

Authors/Creators

Description

Project Description
This paper presents an alternative research model for Pulmonary Sarcoidosis (PS), proposing that the disease may be linked to a chronic, poorly cleared exposure to the common intestinal bacteria Bacteroides fragilis (ETBF) via the gut-lung axis. Compiled from a comprehensive five-year review of literature and clinical data, this framework explores the specific molecular connections between gastrointestinal health, common medications, and inflammatory lung disease.
 
Key Mechanics Explored
  • The Medication Link: The paper examines the clinical observation of dormant sarcoidosis reactivating after long-term treatment with proton pump inhibitors (PPIs) like esomeprazole. It details how these medications change gastrointestinal pH to approximately 6.5, which represents the optimal environment for both B. fragilis growth and the activation of its primary enterotoxin, fragilysin.
  • The Immune Paradox: It provides a potential explanation for why sarcoidosis patients experience intense, localized immune activity in the lungs while showing unreactive "anergy" in peripheral blood tests. The paper maps this pattern to the unique properties of the B. fragilis capsular antigen, Polysaccharide A (PSA).
  • The Metabolic Signature: The model addresses the specific metabolomic markers seen in active sarcoidosis, such as a severe depletion of succinate and glutamine. It suggests this depletion could be caused by direct bacterial consumption as the organism utilizes its unique anaerobic respiration pathways to survive in the hypoxic environment of the lungs.
 
Proposed Therapeutic Approaches
Rather than relying on non-specific corticosteroids or broad-spectrum antibiotics, the paper suggests exploring two targeted interventions:
  1. Zinc-Chelating Hydroxamates: Small molecules designed to block the zinc-dependent motifs of bacterial toxins while simultaneously helping restore regular host regulatory T-cell control.
  2. Mucosal Immune Priming: The targeted oral delivery of purified zwitterionic PSA to retrain immune cells in the gut, promoting systemic tolerance to safely quiet the overactive immune loops in the respiratory tree.
The paper includes a detailed critical discussion of its own limitations—including the structural differences between bacterial abscesses and non-caseating granulomas—and concludes with an explicit human clinical trial protocol to allow independent researchers to test and validate these hypotheses empirically.

Files

The etbf Sarcoidosis Paradigm2.pdf

Files (1.4 MB)

Name Size Download all
md5:5c93c17951f831e18cb69575f316b7f1
1.4 MB Preview Download